The present invention provides fused heterocyclicderivatives represented by the following general formula (I)or pharmaceutically acceptable salts thereof, or prodrugsthereof, which exhibit an inhibitory activity in human SGLT andare useful as agents for the prevention or treatment of a diseaseassociated with hyperglycemia such as diabetes, postprandialhyperglycemia, impaired glucose tolerance, diabeticcomplications or obesity, in the formula R1 to R4 represent H,OH, an amino group, etc.； R5 and R6 represent H, OH, a halogenatom, an optionally substituted alkyl group, etc.； Q representsalkylene, alkenylene, etc.； ring A represents an aryl group ora heteroaryl group； the following ring (R1) represents a grouprepresented by the following ring (R2)； G represents a grouprepresented by the following general formula (G-1) or (G-2) (E1represents H, F or OH； and E2 represents H, F, a methyl group,etc.), and pharmaceutical compositions comprising the same, andpharmaceutical uses thereof.(see formula I)(see formula R1)(see formula II), (see formula III), (see formula R2), (see formula IV) or(see formula V)(see formula G-1)(see formula G-2)
